A diabetes-and-heart drug may also be quietly disarming dangerous blood clots

Sotagliflozin is prescribed to protect the hearts of certain patients with diabetes and heart failure. A University of Michigan team now thinks they know part of why: the drug makes platelets — the blood cells that form clots — less eager to clump. In mouse experiments, clot formation fell by about 60%, and removing the protein the drug targets from platelets alone cut clotting by about 40%, with no sign of disturbing normal bleeding control in the models. The study, in the Journal of Clinical Investigation, gives doctors a clearer lead on how the medicine protects — and what to test next in patients.

SDG 3 · Good health and well-being — Mechanism: tech innovation